Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Bidding war?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2401)
•••
Comment by JDavenporton Feb 25, 2022 12:13pm
165 Views
Post# 34461848

RE:RE:RE:RE:RE:RE:RE:Bidding war?

RE:RE:RE:RE:RE:RE:RE:Bidding war?Read your latest post again, Aarcor, and then we'll discuss mental issues.

About non-disclosure agreements, I have two of them with Bioasis, one for my first contract and the other for the latest contract signed in February, 2019, before the CEO position defaulted to DrDR. Both NDA's remain in force. You can take it to the bank that I know stuff that others don't know. I wrote an earlier Bioasis website. I wrote press releases. I prepared BoD meeting agendas. I sat in on science meetings. It may be of interest that because of what I know, I still support xB3, Bioasis and its shareholders. You don't support anything of interest, Aarcor.

This has become a personal issue for you, Aarcor. You've become very ugly. That very much pleases me. It exposes your character and exposes the fact that, as with beenthere, all you know about Bioasis has been learned by looking at the calendar.

Tough, intelligent people do not need to resort to behaviours like yours, Aarcor. Keep it up. It saves me a lot of work.

jd

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities